Back to top
more

DexCom (DXCM)

(Delayed Data from NSDQ)

$124.34 USD

124.34
8,577,518

-13.67 (-9.91%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $124.45 +0.11 (0.09%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (94 out of 252)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for DXCM

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

DexCom, Inc. [DXCM]

Reports for Purchase

Showing records 381 - 400 ( 411 total )

Company: DexCom, Inc.

Industry: Medical - Products

Record: 381

08/03/2011

Company Report

Pages: 8

Reports Decent Q2 Financials. Core Business Continues To Perform Well and Gen4 on Track for Mid-2012 Launch.

Provider: WEDBUSH SECURITIES INC.

Analyst: LAU R

Price: 25.00

Research Provided by a Third Party

Company: DexCom, Inc.

Industry: Medical - Products

Record: 382

08/01/2011

Company Report

Pages: 5

Q2 Preview - HOLD

Provider: CAPSTONE INVESTMENTS

Analyst: PUTNAM J

Price: 10.00

Research Provided by a Third Party

Company: DexCom, Inc.

Industry: Medical - Products

Record: 383

06/29/2011

Company Report

Pages: 8

Corporate Update: Key Takeaways from ADA Conference

Provider: WEDBUSH SECURITIES INC.

Analyst: LAU R

Price: 25.00

Research Provided by a Third Party

Company: DexCom, Inc.

Industry: Medical - Products

Record: 384

06/21/2011

Company Report

Pages: 8

FDA releases draft guidelines for artificial pancreas system precursor

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: DexCom, Inc.

Industry: Medical - Products

Record: 385

06/09/2011

Company Report

Pages: 32

Halfway to tipping point; initiating with HOLD, $16.25 PT

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 75.00

Research Provided by a Third Party

Company: DexCom, Inc.

Industry: Medical - Products

Record: 386

05/26/2011

Company Report

Pages: 8

Price: 24.95

Company: DexCom, Inc.

Industry: Medical - Products

Record: 387

05/09/2011

Company Report

Pages: 5

Meets Q1 Expectations - Stock Richly Valued - HOLD

Provider: CAPSTONE INVESTMENTS

Analyst: PUTNAM J

Price: 10.00

Research Provided by a Third Party

Company: DexCom, Inc.

Industry: Medical - Products

Record: 388

05/04/2011

Company Report

Pages: 9

Q1 Financials In-Line With Strong Demand Exiting Quarter.

Provider: WEDBUSH SECURITIES INC.

Analyst: LAU R

Price: 25.00

Research Provided by a Third Party

Company: DexCom, Inc.

Industry: Medical - Products

Record: 389

05/02/2011

Daily Note

Pages: 12

Medical Device Q1 Earnings Preview

Provider: CAPSTONE INVESTMENTS

Analyst: PUTNAM J

Price: 25.00

Research Provided by a Third Party

Company: DexCom, Inc.

Industry: Medical - Products

Record: 390

03/08/2011

Company Report

Pages: 8

Price: 24.95

Company: DexCom, Inc.

Industry: Medical - Products

Record: 391

03/04/2011

Company Report

Pages: 5

Strong Close To 2010 -HOLD On Valuation

Provider: CAPSTONE INVESTMENTS

Analyst: PUTNAM J

Price: 10.00

Research Provided by a Third Party

Company: DexCom, Inc.

Industry: Medical - Products

Record: 392

03/04/2011

Company Report

Pages: 8

Q4 Financials: Core Business Remains Solid With Potential for Upside to Guidance in 2011. Raising Fair Value to $17.

Provider: WEDBUSH SECURITIES INC.

Analyst: LAU R

Price: 25.00

Research Provided by a Third Party

Company: DexCom, Inc.

Industry: Medical - Products

Record: 393

03/02/2011

Company Report

Pages: 5

EXPECT STRONG 2010

Provider: CAPSTONE INVESTMENTS

Analyst: PUTNAM J

Price: 10.00

Research Provided by a Third Party

Company: DexCom, Inc.

Industry: Medical - Products

Record: 394

01/12/2011

Company Report

Pages: 8

Q4:10 Preannouncement and 2011 Guidance Both Positive In Our View

Provider: WEDBUSH SECURITIES INC.

Analyst: LAU R

Price: 25.00

Research Provided by a Third Party

Company: DexCom, Inc.

Industry: Medical - Products

Record: 395

12/17/2010

Company Report

Pages: 7

Corporate Update: 2011 Outlook and Recent Financing.

Provider: WEDBUSH SECURITIES INC.

Analyst: LAU R

Price: 25.00

Research Provided by a Third Party

Company: DexCom, Inc.

Industry: Medical - Products

Record: 396

12/03/2010

Company Report

Pages: 8

Price: 24.95

Company: DexCom, Inc.

Industry: Medical - Products

Record: 397

11/11/2010

Industry Report

Pages: 8

INCREASED FDA SCRUTINY LEADING TO LONGER APPROVAL TIMES

Provider: CAPSTONE INVESTMENTS

Analyst: PUTNAM J

Price: 25.00

Research Provided by a Third Party

Company: DexCom, Inc.

Industry: Medical - Products

Record: 398

11/05/2010

Company Report

Pages: 5

MEETS Q3 ESTIMATES- STOCK RICHLY VALUED -HOLD.

Provider: CAPSTONE INVESTMENTS

Analyst: PUTNAM J

Price: 10.00

Research Provided by a Third Party

Company: DexCom, Inc.

Industry: Medical - Products

Record: 399

11/05/2010

Company Report

Pages: 9

Reported a decent Q3

Provider: WEDBUSH SECURITIES INC.

Analyst: LAU R

Price: 25.00

Research Provided by a Third Party

Company: DexCom, Inc.

Industry: Medical - Products

Record: 400

08/26/2010

Daily Note

Pages: 21

THE NEXT PERFECT STORM-OBAMACARE WILL STRETCH THE SYSTEM TO ITS ULTIMATE LIMIT

Provider: CAPSTONE INVESTMENTS

Analyst: PUTNAM J

Price: 75.00

Research Provided by a Third Party